Clinical use and pharmacological properties of selective COX-2 inhibitors

@article{Shi2007ClinicalUA,
  title={Clinical use and pharmacological properties of selective COX-2 inhibitors},
  author={Shao-jun Shi and Ulrich Klotz},
  journal={European Journal of Clinical Pharmacology},
  year={2007},
  volume={64},
  pages={233-252}
}
  • S. Shi, U. Klotz
  • Published 2007
  • Medicine
  • European Journal of Clinical Pharmacology
Selective COX-2 inhibitors (coxibs) are approved for the relief of acute pain and symptoms of chronic inflammatory conditions such as osteoarthritis (OA) and rheumatoid arthritis (RA). They have similar pharmacological properties but a slightly improved gastrointestinal (GI) safety profile if compared to traditional nonsteroidal anti-inflammatory drugs (tNSAIDs). However, long-term use of coxibs can be associated with an increased risk for cardiovascular (CV) adverse events (AEs). For this… Expand
Selective cyclooxygenase-2 inhibitors in dentistry: limitations and adverse effects
TLDR
The coxibs should be used in patients over 60 years, with a history of peptic ulcer or gastrointestinal bleeding, chronic users of corticosteroids and anticoagulants without concomitant cardiovascular risk, and in dentistry, where there is no major evidence of the benefits of using these drugs compared to traditional NSAIDs. Expand
Pharmacokinetics and pharmacodynamics of some NSAIDs in horses: A pharmacological, biochemical and forensic study
TLDR
Investigation of the effects of the two coxib NSAIDs in six retired race horses found that both drugs have no adverse side effects in the horse and their metabolites are completely eliminated within 120 hours following oral administration. Expand
Selective inhibition of cyclooxygenase-2: risks and benefits.
TLDR
The mechanisms underlying the cardiovascular effects are discussed, pointing out the advantages and disadvantages of the selective or nonselective COX inhibitors. Expand
Nonsteroidal Anti-Inflammatory Drugs and the Kidney
TLDR
This review summarizes the present knowledge how traditional NSAIDs and selective COX-2 inhibitors may affect the kidney under various experimental and clinical conditions, and how these drugs may influence renal inflammation, water transport, sodium and potassium balance and how renal dysfunction or hypertension may result. Expand
Structure-activity relationships for the synthesis of selective cyclooxygenase 2 inhibitors: an overview (2009-2016).
TLDR
This manuscript highlights the structure-activity relationships which characterize the chemical scaffolds endowed with selective COX-2 inhibition and the role of COx-2 inhibitors in the pain phenomenon and cancer is discussed. Expand
Adverse Effects of Nonsteroidal Anti-inflammatory Drugs on the Cardiovascular System
Nonsteroidal anti-inflammatory drugs (NSAIDs) are very effective medications, but their use is associated with a broad spectrum of adverse reactions involving the liver, kidney, cardiovascular (CV)Expand
Celecoxib for the Right Person at the Right Dose and Right Time: An Updated Overview
TLDR
Celecoxib should be used with caution in patients known or suspected to be poor CYP2C9 metabolizers and further studies are still needed to confirm their role in the administration of celecoxib to the right person at the right dose and right time. Expand
Proton pump inhibitors: an update of their clinical use and pharmacokinetics
TLDR
This update of pharmacokinetic, pharmacodynamic, and clinical data will provide the necessary guide by which to select between the various PPIs that differ—based on pharmacodynamic assessments—in their relative potencies. Expand
Celecoxib in Cancer Therapy and Prevention - Review.
TLDR
Both preclinical and clinical studies have demonstrated promising results of the role of celecoxib in the treatment and prevention of cancer - the best outcome was observed in colon, breast, prostate and head and neck cancers. Expand
Celecoxib in the Treatment of Osteoarthritis
TLDR
This review illustrates how best to consider selective COX-2 inhibitors role in the current treatment of pain associated with arthritis with an emphasis on osteoarthritis. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 235 REFERENCES
COX-2 inhibitors and the heart: are all coxibs the same?
TLDR
The take home message for prescribing NSAIDs and those coxibs still on the market seems to be one of caution rather than contraindication, except in patients with significant cardiovascular risk factors. Expand
Clinical pharmacology of novel selective COX-2 inhibitors.
TLDR
Several randomized clinical studies suggest that the novel coxibs have comparable efficacy to nonselective NSAIDs in the treatment of osteoarthritis, rheumatoid arthritis and acute pain, but they share similar renal side-effects. Expand
Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib
Celecoxib, a nonsteroidal anti-inflammatory drug (NSAID), is the first specific inhibitor of cyclo-oxygenase-2 (COX-2) approved to treat patients with rheumatism and osteoarthritis. Preliminary dataExpand
Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis.
TLDR
Celecoxib has shown significant equivalent anti-inflammatory and analgesic efficacy and has produced less endoscopically apparent gastrointestinal (GI) ulceration or erosion than have 3 classic NSAIDs. Expand
Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials.
TLDR
The risks for renal AEs with etoricoxib 60, 90, and 120mg/d were low, with a shallow dose response, and were generally similar to those found with the comparator NSAIDs naproxen 1000 mg/d and ibuprofen 2400 mg/D. Expand
Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks.
TLDR
An updated overview on the functions of COX-2 in the cardiovascular system is provided addressing key issues that could help to understand why chronic COx-2 inhibition may have undesirable effects in patients at cardiovascular risk. Expand
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
TLDR
In this study, celecoxib, at dosages greater than those indicated clinically, was associated with a lower incidence of symptomatic ulcers and ulcer complications combined, as well as other clinically important toxic effects, compared with NSAIDs at standard dosages. Expand
Selective Cyclooxygenase-2 Inhibitors Development in Cardiovascular Medicine
TLDR
Concern is whether the reported cardiovascular effects of rofecoxib are a class effect applicable to all coxibs that were initially designed to reduce the gastric toxicity of nonselective COX inhibitors. Expand
Pharmacodynamic of cyclooxygenase inhibitors in humans.
TLDR
The results of clinical pharmacology of COX inhibitors support the concept that the inhibition of platelet COX-1 may translate into an increased incidence of serious upper gastrointestinal bleeding but this effect on platelets may mitigate the cardiovascular hazard associated with the profound inhibition of COx-2-dependent prostacyclin (PGI2). Expand
[Cardiovascular events: a class effect by COX-2 inhibitors].
TLDR
Non-steroidal anti-inflamatories (NSAIDs) are widely used in the treatment of post-surgery pain, rheumatoid arthritis, and muscle-skeletal pain in different conditions and it is believed that COX-1 also plays a role in pathologic conditions such as inflammation. Expand
...
1
2
3
4
5
...